Yoon Hang “John” Kim, MD, MPH

Board-Certified in Preventive Medicine | Integrative & Functional Medicine MD www.directintegrativecare.com

Abstract

Vitamin D has emerged as a pleiotropic immunomodulatory hormone with significant effects on mast cell biology. Mast cells, which are central effectors in allergic disease and increasingly recognized as drivers of mast cell activation syndrome (MCAS), express the vitamin D receptor (VDR). Binding of calcitriol (1,25-dihydroxyvitamin D) to VDR alters transcription of inflammatory mediators, suppresses IgE-dependent activation, and stabilizes mast cells against spontaneous degranulation. Preclinical evidence demonstrates that vitamin D deficiency promotes auto-activation of mast cells and amplifies allergic responses, whereas sufficient or supplemented vitamin D attenuates histamine release, pro-inflammatory cytokine production, and vascular endothelial growth factor (VEGF) signaling. Longer-term vitamin D exposure induces mast cell apoptosis and impairs precursor maturation, suggesting potential for reducing overall mast cell burden. Clinical observations consistently link low 25-hydroxyvitamin D (25-OHD) levels with increased severity of urticaria, atopic disease, and MCAS symptoms. Although robust randomized controlled trials specifically targeting MCAS remain limited, the convergence of mechanistic data and clinical observations supports routine screening and correction of vitamin D deficiency as an adjunct to established MCAS therapies. This review synthesizes the current preclinical and clinical evidence, outlines the mechanistic pathways by which vitamin D modulates mast cell function, and discusses practical implications for integrative management of MCAS.

Keywords: vitamin D, calcitriol, mast cells, mast cell activation syndrome, MCAS, VDR, histamine, IgE, immunomodulation, integrative medicine

1. Introduction

Mast cell activation syndrome (MCAS) is a condition characterized by episodic, excessive, and inappropriate release of mediators from mast cells, producing a constellation of symptoms spanning multiple organ systems. The clinical presentation of MCAS includes flushing, urticaria, gastrointestinal disturbance, cardiovascular instability, and neuropsychiatric manifestations. As recognition of MCAS has grown, so has interest in identifying modifiable factors that influence mast cell stability and reactivity.

Vitamin D, a secosteroid hormone traditionally associated with calcium homeostasis and bone metabolism, has been increasingly recognized for its broad immunomodulatory properties. The discovery that mast cells express the vitamin D receptor (VDR) opened a line of inquiry into whether vitamin D status directly influences mast cell behavior. A growing body of preclinical evidence now demonstrates that vitamin D functions as a mast cell–modulating agent: deficiency promotes spontaneous activation and mediator release, whereas adequate or supplemented vitamin D stabilizes mast cells and dampens both IgE-dependent and cytokine-driven activation pathways.

This article reviews the mechanistic evidence for vitamin D’s effects on mast cells, examines the clinical data linking vitamin D status to mast cell–driven disease, and discusses the practical implications for clinicians managing patients with MCAS and related conditions.

2. Vitamin D Receptor Expression on Mast Cells

Mast cells express the VDR, establishing the molecular basis for direct vitamin D signaling in these cells. When calcitriol (1,25-dihydroxyvitamin D₃) binds to VDR on mast cells, it alters the transcription of inflammatory mediators and intracellular signaling proteins. Notably, calcitriol exposure upregulates VDR expression itself, suggesting a positive feedback mechanism by which adequate vitamin D status maintains mast cell responsiveness to this stabilizing signal.

The VDR-mediated transcriptional changes are extensive. Calcitriol binding reduces FcεRI-mediated signaling through the Lyn–Syk–MAPK–NF-κB pathway, a central cascade in IgE-dependent mast cell activation. Additionally, vitamin D induces epigenetic modifications at the TNF-α promoter region, directly lowering transcription of this key pro-inflammatory cytokine. These findings indicate that vitamin D’s effects on mast cells are not merely permissive but actively regulatory, operating at multiple levels of the signaling and transcriptional architecture.

3. Mechanistic Effects on Mast Cell Function

3.1 Suppression of IgE-Dependent Activation

Vitamin D₃ metabolites, including both 25-hydroxyvitamin D₃ (25-OHD₃) and calcitriol, suppress IgE-dependent mast cell activation in experimental models. This suppression manifests as reduced degranulation and decreased release of preformed mediators such as histamine and tryptase. In animal and human skin models, both topical and systemic vitamin D₃ administration reduces immediate-phase and late-phase allergic responses, with measurable decreases in histamine and leukotriene release from mast cells.

Murine models further demonstrate that systemic vitamin D sufficiency lessens allergen sensitization and attenuates allergic airway inflammation, whereas vitamin D deficiency enhances allergic manifestations and amplifies mast cell–driven responses. These findings suggest that vitamin D status may serve as a modifiable determinant of the threshold for allergic activation.

3.2 Mast Cell Stabilization and Apoptosis

Preclinical work has established that vitamin D is “required to maintain the stability of mast cells.” In vitamin D–deficient conditions, mast cells spontaneously activate and release mediators without an external trigger—a phenomenon that may be directly relevant to the clinical picture of MCAS, where patients experience unprovoked flares. Calcitriol exposure stabilizes mast cells through VDR–Lyn interactions and downstream signaling changes that raise the activation threshold.

Longer-term vitamin D₃ exposure (approximately 30–40 days in cell culture models) induces mast cell apoptosis and impairs the differentiation and maturation of mast cell precursors. This dual effect—stabilizing existing mast cells while reducing the generation of new ones—raises the possibility that sustained vitamin D sufficiency could lower overall mast cell burden over time, a concept with significant therapeutic implications for chronic mast cell–mediated disease.

3.3 Cytokine Modulation and Anti-Inflammatory Effects

Vitamin D₃ modulates cyclooxygenase (COX) activity and prostaglandin synthesis within mast cells, and reduces the production of pro-inflammatory cytokines including interleukin-1 (IL-1), interleukin-6 (IL-6), interleukin-33 (IL-33), and tumor necrosis factor alpha (TNF-α). Concurrently, vitamin D supports the production of anti-inflammatory mediators, most notably interleukin-10 (IL-10), shifting the overall cytokine balance toward immune tolerance.

The suppression of TNF-α production occurs through reduced MAPK/NF-κB activation and chromatin remodeling at inflammatory gene promoters, representing a mechanism that operates at the epigenetic level. This is significant because TNF-α is a major driver of both local tissue inflammation and systemic symptoms in MCAS, and its suppression by vitamin D may contribute to symptom reduction independently of mast cell stabilization per se.

3.4 VEGF, Vascular Permeability, and Urticaria

In chronic spontaneous urticaria (CSU) models, vitamin D reduces mast cell production of vascular endothelial growth factor (VEGF) by inhibiting the PI3K/Akt/p38 MAPK/HIF-1α signaling axis. VEGF is a potent mediator of vascular permeability and is implicated in wheal formation, the hallmark lesion of urticaria. By suppressing VEGF production at the mast cell level, vitamin D may directly mitigate the vascular component of allergic and mast cell–mediated skin disease.

This finding aligns with clinical data demonstrating that patients with low vitamin D levels experience more severe urticaria, and it provides a mechanistic bridge between vitamin D deficiency and the vascular pathology that underlies visible symptoms in both urticaria and MCAS-related flushing.

4. Vitamin D Deficiency, MCAS, and Clinical Observations

Clinical commentary and systematic reviews on MCAS report a high prevalence of vitamin D deficiency among affected patients. This observation is consistent with the mechanistic framework: in the absence of adequate calcitriol-VDR signaling, mast cells lose a key stabilizing input and become prone to inappropriate activation. The clinical consequences include heightened baseline symptom burden, increased flare frequency, and potentially greater severity of individual episodes.

Supportive but indirect human evidence includes the association between low 25-OHD levels and worse outcomes in allergic, atopic, and urticarial disease. Some studies of chronic urticaria have demonstrated improvement with vitamin D supplementation, presumably mediated through combined mast cell and T-cell effects. Patient advocacy and functional medicine resources have similarly noted that vitamin D deficiency may itself serve as a trigger or exacerbating factor for mast cell activation and associated muscular or systemic symptoms.

It is important to note, however, that most of the rigorous mechanistic data derive from preclinical systems—cell lines, murine models, and skin provocation tests. Robust randomized controlled trials specifically enrolling MCAS populations and using vitamin D supplementation as an intervention remain lacking. The clinical evidence, while consistent and directionally supportive, does not yet meet the standard of Level I evidence for MCAS-specific vitamin D therapy.

5. Practical Implications for Integrative MCAS Management

Given the strength and consistency of the mechanistic evidence, several clinical actions are justified as evidence-congruent, even in the absence of definitive MCAS-specific trial data.

5.1 Screening and Repletion

All patients with MCAS, chronic spontaneous urticaria, or significant atopic disease should be screened for 25-OHD deficiency. When deficiency is identified, repletion to at least generally accepted sufficiency ranges should be undertaken with appropriate monitoring of serum calcium and renal function. The mechanistic rationale for this intervention is strong: correcting deficiency restores a physiologically important stabilizing signal to mast cells, a signal that is absent or attenuated in the deficient state.

5.2 Adjunctive Role in MCAS Therapy

Vitamin D should be framed as an adjunct to established MCAS therapies—including H1 and H2 receptor antagonists, cromolyn sodium, leukotriene receptor antagonists, and other mast cell–directed agents—rather than as a stand-alone controller. The mechanistically justified roles for vitamin D in this context include mast cell stabilization, anti-inflammatory and immune modulation (via VDR signaling on mast cells, dendritic cells, and regulatory T cells), and possible long-term reduction of mast cell burden through apoptosis induction and impaired precursor maturation.

5.3 Dosing Considerations and Safety

High-dose vitamin D supplementation carries the risk of hypercalcemia and may theoretically influence other immune pathways in complex, multi-system patients. Individual titration and monitoring remain important. Clinicians should avoid the temptation to pursue supraphysiologic dosing in the absence of trial data supporting specific targets in MCAS. A conservative approach—correct deficiency, achieve sufficiency, and monitor—is most consistent with the current evidence base.

6. Future Directions

The field requires well-designed randomized controlled trials that specifically enroll MCAS patients and evaluate vitamin D supplementation as an intervention, with validated symptom scores and biomarker endpoints (including serum tryptase, urinary prostaglandin metabolites, and 25-OHD levels). Such trials should define optimal dosing strategies, target 25-OHD levels, and expected effect sizes.

Additionally, research into the epigenetic mechanisms by which vitamin D modulates mast cell gene expression—particularly at the TNF-α and VEGF promoters—may yield insights applicable to broader inflammatory and autoimmune conditions. The observation that prolonged vitamin D exposure can induce mast cell apoptosis and impair precursor maturation warrants further investigation as a potential disease-modifying mechanism, as distinct from the symptom-modifying effects of acute mast cell stabilization.

7. Conclusion

Vitamin D functions as a mast cell–modulating hormone with effects spanning IgE-dependent activation, spontaneous degranulation, cytokine production, VEGF signaling, and mast cell survival. The mechanistic evidence is substantial and consistent: vitamin D deficiency destabilizes mast cells and promotes activation, while adequacy or supplementation stabilizes mast cells, reduces inflammatory mediator release, and may lower mast cell burden over time.

For clinicians managing MCAS and related mast cell–driven conditions, these data support routine screening and correction of vitamin D deficiency as a mechanistically justified adjunct to standard therapies. While definitive MCAS-specific clinical trials are needed to establish dosing protocols and quantify clinical benefit, the risk–benefit profile of correcting vitamin D deficiency is highly favorable, and the preclinical rationale is among the most robust of any proposed adjunctive intervention in MCAS.

References

1. Yip KH, Kolesnikoff N, Yu C, et al. Mechanisms of vitamin D₃ metabolite repression of IgE-dependent mast cell activation. J Allergy Clin Immunol. 2014;133(5):1356–1364.

2. Liu ZQ, Li XX, Qiu SQ, et al. Vitamin D contributes to mast cell stabilization. Allergy. 2017;72(8):1184–1192.

3. Biggs L, Yu C, Bhardwaj N, et al. Evidence that vitamin D₃ promotes mast cell–dependent reduction of chronic UVB-induced skin pathology in mice. J Exp Med. 2010;207(3):455–463.

4. Heine G, Niesner U, Chang HD, et al. 1,25-dihydroxyvitamin D₃ promotes IL-10 production in human B cells. Eur J Immunol. 2008;38(8):2210–2218.

5. Baroni E, Biffi M, Benigni F, et al. VDR-dependent regulation of mast cell maturation mediated by 1,25-dihydroxyvitamin D₃. J Allergy Clin Immunol. 2007;120(4):826–834.

6. Siddiqui M, Golam K, Engwall K, et al. Vitamin D deficiency and chronic spontaneous urticaria: a systematic review. Allergy Asthma Clin Immunol. 2020;16:83.

7. Wang M, Wang K, Gao X, et al. Vitamin D inhibits VEGF production of mast cells via PI3K/Akt/p38 MAPK/HIF-1α pathway. Cytokine. 2020;128:155010.

8. Tsilioni I, Theoharides TC. Vitamin D reduces mast cell–derived inflammatory cytokines and chemokines. J Cell Mol Med. 2020;24(14):8095–8101.

9. Afrin LB, Ackerley MB, Bluestein LS, et al. Diagnosis of mast cell activation syndrome: a global “consensus-2.” Diagnosis. 2021;8(2):137–152.

10. Molderings GJ, Brettner S, Homann J, Afrin LB. Mast cell activation disease: a concise practical guide for diagnostic workup and therapeutic options. J Hematol Oncol. 2011;4:10.

About the Author

Yoon Hang “John” Kim, MD, MPH is a board-certified integrative medicine physician with over 20 years of clinical experience. He completed his integrative medicine fellowship at the University of Arizona under Dr. Andrew Weil and holds certifications in preventive medicine, medical acupuncture (UCLA), and integrative/holistic medicine. Dr. Kim is an Osher Fellow and Institute for Functional Medicine scholar whose career has spanned academic medicine, community health, and integrative oncology across diverse settings throughout the United States, including roles at Miami Cancer Institute, University of Kansas Medical Center, and Memorial Hospital.

Dr. Kim is the founder and physician of Direct Integrative Care, a membership-based telemedicine practice serving patients across multiple states (Iowa, Illinois, Missouri, Texas, Georgia, and Florida). His practice model deliberately limits enrollment to 99 patients to ensure deeply personalized, relationship-centered care outside of insurance-based systems.

A recognized authority on low dose naltrexone (LDN) therapy, Dr. Kim has authored three books and over 20 articles on LDN and integrative medicine, and has presented at LDN Research Trust conferences. He leads an LDN Support Group with over 7,000 members and is currently developing the 2026 edition of his LDN book.

His personal motto—“Luck favors the prepared bold”—reflects his approach to both clinical practice and life.

Practice Website: www.directintegrativecare.com

Fees & Services: directintegrativecare.com/integrative-medicine-direct-care-fees